The Hepatitis C Genotype 1 Paradox: Cost per Treatment Is Increasing, but Cost per Cure Is Decreasing
Significant attention has been focused on the perceived increase in the cost of antiviral treatment for hepatitis C genotype 1 infection since the approval of the first direct-acting antiviral agents in 2011. Using Canadian list prices, the present analysis points out a paradox: while the cost per a...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2015-01-01
|
| Series: | Canadian Journal of Gastroenterology and Hepatology |
| Online Access: | http://dx.doi.org/10.1155/2015/216395 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832558790148358144 |
|---|---|
| author | Stephen D Shafran |
| author_facet | Stephen D Shafran |
| author_sort | Stephen D Shafran |
| collection | DOAJ |
| description | Significant attention has been focused on the perceived increase in the cost of antiviral treatment for hepatitis C genotype 1 infection since the approval of the first direct-acting antiviral agents in 2011. Using Canadian list prices, the present analysis points out a paradox: while the cost per antiviral regimen is increasing, the cost per cure is decreasing, especially with interferon-free therapy. In a publicly funded health care system, the lowest cost per cure is a more valuable measure of value for public money than the cost per regimen. |
| format | Article |
| id | doaj-art-3e00898b14f14ec0b40154c97005c15f |
| institution | Kabale University |
| issn | 2291-2789 2291-2797 |
| language | English |
| publishDate | 2015-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Canadian Journal of Gastroenterology and Hepatology |
| spelling | doaj-art-3e00898b14f14ec0b40154c97005c15f2025-02-03T01:31:32ZengWileyCanadian Journal of Gastroenterology and Hepatology2291-27892291-27972015-01-01291464810.1155/2015/216395The Hepatitis C Genotype 1 Paradox: Cost per Treatment Is Increasing, but Cost per Cure Is DecreasingStephen D Shafran0Division of Infectious Diseases, Department of Medicine, University of Alberta, Edmonton, Alberta, CanadaSignificant attention has been focused on the perceived increase in the cost of antiviral treatment for hepatitis C genotype 1 infection since the approval of the first direct-acting antiviral agents in 2011. Using Canadian list prices, the present analysis points out a paradox: while the cost per antiviral regimen is increasing, the cost per cure is decreasing, especially with interferon-free therapy. In a publicly funded health care system, the lowest cost per cure is a more valuable measure of value for public money than the cost per regimen.http://dx.doi.org/10.1155/2015/216395 |
| spellingShingle | Stephen D Shafran The Hepatitis C Genotype 1 Paradox: Cost per Treatment Is Increasing, but Cost per Cure Is Decreasing Canadian Journal of Gastroenterology and Hepatology |
| title | The Hepatitis C Genotype 1 Paradox: Cost per Treatment Is Increasing, but Cost per Cure Is Decreasing |
| title_full | The Hepatitis C Genotype 1 Paradox: Cost per Treatment Is Increasing, but Cost per Cure Is Decreasing |
| title_fullStr | The Hepatitis C Genotype 1 Paradox: Cost per Treatment Is Increasing, but Cost per Cure Is Decreasing |
| title_full_unstemmed | The Hepatitis C Genotype 1 Paradox: Cost per Treatment Is Increasing, but Cost per Cure Is Decreasing |
| title_short | The Hepatitis C Genotype 1 Paradox: Cost per Treatment Is Increasing, but Cost per Cure Is Decreasing |
| title_sort | hepatitis c genotype 1 paradox cost per treatment is increasing but cost per cure is decreasing |
| url | http://dx.doi.org/10.1155/2015/216395 |
| work_keys_str_mv | AT stephendshafran thehepatitiscgenotype1paradoxcostpertreatmentisincreasingbutcostpercureisdecreasing AT stephendshafran hepatitiscgenotype1paradoxcostpertreatmentisincreasingbutcostpercureisdecreasing |